A New Strategy Based on Smrho Protein Loaded Chitosan Nanoparticles as a Candidate Oral Vaccine against Schistosomiasis

PLoS Neglected Tropical Diseases

Volumn 6, Issue 11, 2012, Pages

  Oliveira, Carolina R ^a   Rezende, Cíntia M F ^a   Silva, Marina R ^a   Pêgo, Ana Paula ^b,c   Borges, Olga ^d,e   Goes, Alfredo M ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF COIMBRA   (Portugal)

^e UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; CHITOSAN; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; NANOPARTICLE; SCHISTOSOMA VACCINE; SMRHO VACCINE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CPG ISLAND; DRUG STABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRANULOMA; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARTICLE SIZE; SCHISTOSOMIASIS; SCHISTOSOMIASIS MANSONI; SPLEEN CELL; WESTERN BLOTTING; ZETA POTENTIAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ALGINATES; ANIMALS; ANTIGENS, HELMINTH; BODY FLUIDS; CHITOSAN; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG STABILITY; FEMALE; GLUCURONIC ACID; GRANULOMA; HEXURONIC ACIDS; MICE; MICE, INBRED C57BL; NANOPARTICLES; OLIGODEOXYRIBONUCLEOTIDES; SCHISTOSOMIASIS; VACCINES;

EID: 84870751323     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001894     Document Type: Article

References (60)

1. King CH, (2009) Toward the elimination of schistosomiasis. New England Journal of Medicine 360: 106-109.
2. WHO WHO (2010) http://www.who.int/mediacentre/factsheets/fs115/en/index.html. In: N°115 Fs, editor.
3. van der Werf MJ, de Vlas SJ, Brooker S, Looman CWN, Nagelkerke NJD, et al. (2003) Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop 86: 125-139.
4. Harder A, (2002) Chemotherapeutic approaches to schistosomes: current knowledge and outlook. Parasitology Research 88: 395-397.
5. Bergquist NR, Colley DG, (1998) Schistosomiasis vaccine: research to development. Parasitology Today 14: 99-104.
6. Bergquist N, (2002) Schistosomiasis: from risk assessment to control. Trends in Parasitology 18: 309-314.
7. Chitsulo L, Loverde P, Engels D, (2004) Schistosomiasis. Nature Review Microbiology 2: 12-13.
8. McManus DP, Loukas A, (2008) Current status of vaccines for schistosomiasis. Clin Microbiol Rev 21: 225-242.
9. Schüssler P, Grevelding C, Kunz W, (1997) Identification of Ras, MAP kinases, and a GAP protein in Schistosoma mansoni by immunoblotting and their putative involvement in male-female interaction. Parasitology 115: 629-634.
10. Vermeire JJ, Osman A, LoVerde PT, Williams DL, (2003) Characterisation of a Rho homologue of Schistosoma mansoni. Int J Parasitol 33: 721-731.
11. Gryseels B, Polman K, Clerinx J, Kestens L, (2006) Human schistosomiasis. The Lancet 368: 1106-1118.
12. Mishra N, Goyal AK, Tiwari S, Paliwal R, Paliwal SR, et al. (2010) Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers. Expert Opin Ther Pat 20: 661-679.
13. Jabbal-Gill I, Lin W, Jenkins P, Watts P, Jimenez M, et al. (1999) Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines. Vaccine 18: 238-250.
14. Garg N, Mangal S, Khambete H, Tyagi R, (2010) Mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymers. Recent Pat Drug Deliv Formul 4: 114-128.
15. Borges OMF (2007) O uso de nanopartículas de quitosano, revestidas com alginato como adjuvante do antigénio da hepatite B na vacinação através das mucosas oral e nasal. Coimbra- Portugal: Universidade de Coimbra.
16. Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW, (2007) Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine 25: 2085-2094.
17. Reese TA, Liang H-E, Tager AM, Luster AD, Van Rooijen N, et al. (2007) Chitin induces accumulation in tissue of innate immune cells associated with allergy. Nature 447: 92-96.
18. Yasuda K, Muto T, Kawagoe T, Matsumoto M, Sasaki Y, et al. (2012) Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice. PNAS 109: 3451-3456.
19. Porporatto C, Bianco ID, Correa SG, (2005) Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration. J Leuk Biol 78: 62-69.
20. Shibata Y, Honda I, Justice JP, Van Scott MR, Nakamura RM, et al. (2001) Th1 Adjuvant N-Acetyl-d-Glucosamine Polymer Up-Regulates Th1 Immunity but Down-Regulates Th2 Immunity against a Mycobacterial Protein (MPB-59) in Interleukin-10-Knockout and Wild-Type Mice. Infect Immun 69: 6123-6130.
21. Singla AK, Chawla M, (2001) Chitosan: some pharmaceutical and biological aspects- an update. J Pharm Pharmacol 53: 1047-1067.
22. Ranaldi G, Marigliano I, Vespignani I, Perozzi G, Sambuy Y, (2002) The effect of chitosan and other polycations on tight junction permeability in the human intestinal Caco-2 cell line. The Journal of Nutritional Biochemistry 13: 157-167.
23. Mao H, Roy K, Troung-Le VL, Janes KA, Lin KY, et al. (2001) Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release 70: 399-421.
24. Borges O, Borchard G, Verhoef J, de Sousa A, Junginger H, (2005) Preparation of coated nanoparticles for a new mucosal vaccine delivery system. Int J Pharm 299: 155-166.
25. Borges O, Cordeiro-da-Silva A, Romeijn SG, Amidi M, Sousa AD, et al. (2006) Uptake studies in rat peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination. J Control Release 114: 348-358.
26. Neutra MR, Kozlowski PA, (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6: 148-158.
27. Brugnerotto J, Lizardi J, Goycoolea F, Arguelles-Monal W, Desbrieres J, et al. (2001) An infrared investigation in relation with chitin and chitosan characterization. Polymer 42: 3569-3580.
28. Nakagawa Y, Murai T, Hasegawa C, Hirata M, Tsuchiya T, et al. (2003) Endotoxin contamination in wound dressings made of natural biomaterials. Journal of biomedical materials research part B: Applied Biomaterials 66B: 347-355.
29. USP (2005) United States Pharmacopeia,. General Chapter 85- Bacterial Endotoxins Test.
30. Moreira C, Oliveira H, Pires LR, Simões S, Barbosa MA, et al. (2009) Improving chitosan-mediated gene transfer by the introduction of intracellular buffering moieties into the chitosan backbone. Acta Biomater 5: 2995-3006.
31. Oliveira C, Rezende C, Silva M, Borges O, Pêgo A, et al. (2012) Oral Vaccination Based on DNA-Chitosan Nanoparticles against Schistosoma mansoni Infection. TSWJ 2012: 11.
32. Fernandes V, Martins E, Boeloni J, Serakides R, Goes A, (2012) Protective effect of rPb40 as an adjuvant for chemotherapy in experimental paracoccidioidomycosis. Mycopathologia 174: 93-105.
33. Smithers SR, Terry RJ, (1965) The infection of laboratory hosts with cercariae of Schistosoma mansoni and the recovery of the adult worms. Parasitology 55: 695-700.
34. Goes AM, Rocha RS, Gazzinelli G, Doughty BL, (1989) Production and characterization of human monoclonal antibodies against Schistosoma mansoni. Parasite Immunology 11: 695-711.
35. Tang ESK, Huang M, Lim LY, (2003) Ultrasonication of chitosan and chitosan nanoparticles. Int J Pharm 265: 103-114.
36. Bergquist R, Utzinger J, McManus DP, (2008) Trick or Treat: The Role of Vaccines in Integrated Schistosomiasis Control. PLoS Negl Trop Dis 2: e244.
37. Kotton CN, Hohmann EL, (2004) Enteric Pathogens as Vaccine Vectors for Foreign Antigen Delivery. Infect Immun 72: 5535-5547.
38. Benesch J, Tengvall P, (2002) Blood protein adsorption onto chitosan. Biomaterials 23: 2561-2568.
39. Li XY, Kong X, Shi S, Zheng X, Guo G, et al. (2008) Preparation of alginate coated chitosan microparticles for vaccine delivery. BMC Biotechnol 8: 89.
40. O'Hagan DT, Rappuoli R, (2004) Novel approaches to vaccine delivery. Pharm Res 21: 1519-1530.
41. Wang J, Zeng Z, Xiao R, Xie T, Zhou G, et al. (2011) Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomedicine 6: 765-774.
42. Chopra S, Mahdi S, Kaur J, Iqbal Z, Talegaonkar S, et al. (2006) Advances and potential applications of chitosan derivatives as mucoadhesive biomaterials in modern drug delivery. Journal of Pharmacy and Pharmacology 58: 1021-1032.
43. Prego C, Torres D, Alonso MJ, (2005) The potential of chitosan for the oral administration of peptides. Expert Opinion on Drug Delivery 2: 843-854.
44. Cui Z, Mumper R, (2001) Chitosan-based nanoparticles for topical genetic immunization. J Control Release 75: 409-419.
45. Lubben M, Kersten G, Fretz M, Beuvery C, Verhoef J, et al. (2003) Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine 21: 1400-1408.
46. Periwal SB, Speaker TJ, Cebra JJ, (1997) Orally administered microencapsulated reovirus can bypass suckled, neutralizing maternal antibody that inhibits active immunization of neonates. J Virology 71: 2844-2850.
47. Bowersock TL, HogenEsch H, Suckow M, Porter RE, Jackson R, et al. (1996) Oral vaccination with alginate microsphere systems. J Control Release 39: 209-220.
48. Fujihara M, Nagumo T, (1993) An influence of the structure of alginate on the chemotactic activity of macrophages and the antitumor activity. Carbohydrate Research 243: 211-216.
49. Mata E, Igartua M, Patarroyo M, Pedraz J, Hernández R, (2011) Enhancing immunogenicity to PLGA microparticulate systems by incorporation of alginate and RGD-modified alginate. Eur J Pharm Sci 44: 32-40.
50. Wynn TA, Cheever AW, (1995) Cytokine regulation of granuloma formation in schistosomiasis. Curr Opin Immunol 7: 505-511.
51. Jarnicki AG, Conroy H, Brereton C, Donnelly G, Toomey D, et al. (2008) Attenuating Regulatory T Cell Induction by TLR Agonists through Inhibition of p38 MAPK Signaling in Dendritic Cells Enhances Their Efficacy as Vaccine Adjuvants and Cancer Immunotherapeutics. The Journal of Immunology 180: 3797-3806.
52. Slutter B, Jiskoot W, (2010) Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination. J Control Release 148: 117-121.
53. Muzzarelli R, (2010) Chitins and Chitosans as Immunoadjuvants and Non-Allergenic Drug Carriers. Mar Drugs 8: 292-312.
54. Wilson MS, Mentink-Kane MM, Pesce JT, Ramalingam TR, Thompson R, et al. (2007) Immunopathology of schistosomiasis. Immunol Cell Biol 85: 148-154.
55. Wynn TA, (1996) Development of an Antipathology Vaccine for Schistosomiasis. Annals N Y Acad Sci 797: 191-195.
56. Gordon S, (2003) Alternative activation of macrophages. Nat Rev Immunol 3: 23-35.
57. Voehringer D, Reese TA, Huang X, Shinkai K, Locksley RM, (2006) Type 2 immunity is controlled by IL-4/IL-13 expression in hematopoietic non-eosinophil cells of the innate immune system. The Journal of Experimental Medicine 203: 1435-1446.
58. Da Silva CA, Hartl D, Liu W, Lee CG, Elias JA, (2008) TLR-2 and IL-17A in Chitin-Induced Macrophage Activation and Acute Inflammation. J Immunol 181: 4279-4286.
59. Herbert DBR, Hölscher C, Mohrs M, Arendse B, Schwegmann A, et al. (2004) Alternative Macrophage Activation Is Essential for Survival during Schistosomiasis and Downmodulates T Helper 1 Responses and Immunopathology. Immunity 20: 623-635.
60. Wilson RA, Coulson PS, (1998) Why Don't We Have a Schistosomiasis Vaccine? Parasitology Today 14: 97-99.